FDA Email Spying: Crisis Experts Say Agency Needs To Tell Its Story Better
Executive Summary
OIG has launched an investigation of FDA’s pre-market review process after the Office of Special Counsel concluded that two devices approved over the objection of FDA scientists likely pose imminent risk to public.
You may also be interested in...
FDA Hit With Slew Of Suits As Firms Fight For Market Advantage
At least nine complaints have been filed against the agency since March, most involving market exclusivity claims; lawyers expect innovators will be pursuing more cases as patents expire and biosimilars emerge.
FDA Spyware Suit: Whistleblowers Challenge Agency Over Email Surveillance
Six current and former employees of FDA’s device center file suit in the U.S. District Court in Washington, D.C., arguing that email and computer surveillance violated their constitutional and legal whistleblower rights.
FDA's Device Center Faces New Charge Of Whistleblower Retaliation
Federal officials took steps last week to reinstate a recently fired reviewer in FDA's diagnostics office, claiming that agency actions may have violated the Whistleblower Protection Act.